Introduction {#S1}
============

Public interest in cannabis has increased over the last decade for several reasons. First, cannabis is the most popular recreational drug, and its use has increased over time, with population data estimating around 200 million users worldwide ([@B101]). Second, because of ongoing decriminalization and legalization policies ([@B63]; [@B66]), low-potency cannabis varieties have come on to the market as non-medicinal products with recreational and self-medication purposes. These preparations have a legally established limit of Δ-9-tetrahydrocannabinol (Δ9-THC), the main psychoactive ingredient of cannabis, ranging from 0.2 to 1% across countries ([@B117]). Such non-medicinal products contain mainly cannabidiol (CBD), a non-intoxicating cannabinoid ([@B58]), at doses far lower (e.g., 25 mg) than those ever used in human therapeutic trials (e.g., 150--1,500 mg/d) ([@B43]). Some countries have questioned the safety of these so-called "cannabis light" varieties ([@B110]), because of wide variability in cannabinoid profiles in the absence of standardized regulations ([@B104]). Third, in the illicit market, the part of the cannabis plant with the highest Δ9-THC content is selected to amplify its intoxicating effects ([@B117]), with the result that illicit cannabis potency, indexed as Δ-9-THC concentration, has increased over the last 30 years ([@B25]). This leads to a fourth reason for public focus, as accumulating evidence indicates a dose--response relationship between increasing Δ9-THC exposure and harm attributable to or related to cannabis use ([@B59]). Neuropsychiatric and substance use disorders account for the larger part of the burden of disease as measured in disability-adjusted life years ([@B62]), with psychosis and cognitive impairments representing consequences invoked as a result of high-potency cannabis use ([@B30]; [@B47]). Moreover, sustained Δ9-THC exposure has been shown to drive dependence in a non-negligible proportion of users, estimated around 6--7% ([@B44]), and tolerance phenomena ([@B31]), by inducing neurobiological alterations in brain regions relevant to addiction ([@B130]). Finally, a fifth reason is related to the licit production of cannabis for medicinal purposes, which has increased considerably over the last 20 years, growing from 1.4 tons in 2000, mainly for purposes of scientific research, to 211.3 tons by 2016 ([@B72]). Consistent with this, several high-income countries have implemented medicinal programs with cannabis-related medicinal products for a wide range of conditions. Sativex, a cannabis plant--derived oral spray containing Δ9-THC and CBD in a 1:1 ratio, is licensed for the treatment of multiple sclerosis spasticity in Europe, Canada, Australia, Brazil, and Israel and prescribed for chronic pain. Epidiolex, a cannabis plant--derived oral CBD solution, is licensed in the United States and Europe for treatment-resistant severe forms of childhood epilepsy. Dronabinol and nabilone, synthetic compounds chemically similar to Δ9-THC, are licensed in the United States and Europe for weight loss associated with anorexia in AIDS and suboptimally controlled chemotherapy-related nausea. Estimated effectiveness of these medicinal products for the indexed indication is low (Epidiolex, dronabinol) to moderate (Sativex) ([@B58]). Currently, clinical trials are evaluating the effectiveness of these products for different neuropsychiatric conditions, including Tourette syndrome, anxiety disorders, posttraumatic stress disorder, Alzheimer disease, Parkinson disease, psychosis, and schizophrenia ([@B126]; [@B101]; [@B43]).

Cannabis and its main ingredients have been implicated both in the development and worsening as well as in the treatment of psychosis and cognitive dysfunction. This article aims to disentangle the cannabinoid profile of different cannabis varieties with psychotogenic and intoxicating effects from that of preparations with potential therapeutic properties.

Methods {#S2}
=======

This narrative review selectively focuses on the role of different cannabinoids in modulating psychosis and cognition. A literature search was performed using electronic databases (MEDLINE, Web of Science, and Scopus), without any time period limits, using a combination of search terms describing cannabinoids (Δ9-THC, CBD) and cognition (cognitive dysfunction/impairment/performance) or psychosis (psychotic disorder/symptoms/risk). In addition, any relevant research evidence that was not identified by this literature search has also been summarized, if considered appropriate by all authors.

Cannabis, Psychosis, and Cognitive Dysfunction {#S2.SS1}
----------------------------------------------

One main issue about the association between cannabis and psychosis is its nature, namely, whether it reflects a causal relationship ([@B38]). In this perspective, longitudinal studies evaluating whether cannabis use leads to subsequent development of psychosis are of particular interest. Of 13 studies conducted so far, 10 support an increased risk of subsequently developing psychosis among cannabis users ([@B1]; [@B122]; [@B4]; [@B123]; [@B125]; [@B129]; [@B57]; [@B56]; [@B67]; [@B87]; [@B107]; [@B5]). Three more studies find a trend in the same direction failing to reach statistical significance, possibly because of short follow-up periods ([@B127]; [@B61]) or limited sample power ([@B108]).

Some of these studies indicate a higher likelihood of developing psychosis as a function of frequent cannabis use, a good proxy for increasing Δ-9-THC exposure ([@B122]; [@B4]; [@B129]; [@B67]; [@B127]), also confirmed by meta-analytic work ([@B88]). Moreover, escalation of cannabis use in the immediate 5-year premorbid period increases the risk of psychosis onset ([@B77]), with daily and high-potency cannabis use accounting, at least in part, for the higher incidence of psychosis found in some European countries ([@B47]). Also, while patients who stop using cannabis have the most favorable course of illness ([@B34]), daily and high-potency cannabis use has been associated with higher ([@B113]) and dose-dependent ([@B114]) risk of psychosis relapse. Finally, magnetic resonance imaging (MRI) studies support a substantial overlap between the structural ([@B84]), functional ([@B20], [@B21],[@B22]), neurochemical ([@B118]; [@B35]; [@B23]), and structural connectivity ([@B106]) alterations observed upon frequent or high-potency cannabis use and those involved in the pathophysiology of schizophrenia ([@B70]).

Despite the evidence of a prospective association between cannabis and psychosis, it is important to highlight that alternative explanations for such association have been proposed, including the possibility that it might be accounted, at least partially, by the confounding effect of sociodemographic characteristics, preexisting psychiatric conditions, other substance use, self-medication, and shared genetic vulnerability ([@B33]). Drawing conclusions as to whether the observed association represents a cause--effect relationship between exposure and disease is difficult ([@B27]; [@B78]). According to epidemiological criteria to infer causality, cannabis use may be a component cause of psychosis ([@B27]; [@B33]). In particular, the association appears to be of a modest strength, with the risk of psychosis being higher in heavy users carrying specific genetic or neurophysiological vulnerability, while most cannabis users do not develop psychosis ([@B27]; [@B78]; [@B33]).

The long-term effect of cannabis on cognition has been debated even more, because of inhomogeneous impairment across cognitive domains ([@B112]; [@B85]), genetically determined dose--response interindividual variability ([@B120]), and tolerance phenomena ([@B31]; [@B36], [@B37]). As for psychosis, evidence indicates a relationship between frequent ([@B94]) and high-potency ([@B30]) cannabis use and the degree of cognitive impairments, supporting a cumulative adverse effect of Δ9-THC. This is particularly relevant to youth, because of more severe effects on a brain still in development ([@B94]; [@B20], [@B21]; [@B71]). However, cannabis use seems to have a modest overall impact on cognition ([@B116]), with the risk of more pronounced disrupting effects being higher in heavy users with specific biological and behavioral vulnerabilities ([@B73]), while the effects are of limited clinical relevance for most individuals ([@B116]) and generally not enduring following abstinence ([@B115]).

The exact mechanisms underlying the adverse effects of Δ9-THC and its interaction with other cannabinoids present in cannabis used recreationally remain unclear. In fact, the cannabis plant can produce at least 144 cannabinoids, whose effects are mostly unknown ([@B65]). In this regard, controlled experiments administering Δ9-THC and other cannabinoids to healthy people are particularly valuable. When implemented in an MRI design, such challenge studies may elucidate how different cannabinoids modulate human behavior by tracking the acute modulation of related neurobiological processes and their genetic, neurophysiological, and neuroreceptor determinants ([@B8], [@B9], [@B13], [@B11], [@B15]).

Human Laboratory Studies on Cannabinoids and Behavior {#S2.SS2}
-----------------------------------------------------

The most compelling evidence supporting a role of cannabinoids in modulating human behavior comes from experimental studies with Δ9-THC and CBD ([@B14]). Δ-9-Tetrahydrocannabinol can induce transient ([@B52]; [@B9], [@B6]; [@B40]) and less frequently persistent psychotic symptoms needing clinical attention ([@B53]) in otherwise healthy individuals and worsen clinical presentation in psychosis patients ([@B51]). Such psychosis-inducing effect is time locked to drug administration and often occurs at the same time of a transitorily impaired cognitive functioning ([@B42]; [@B32]), due to perturbation of underlying brain activity ([@B12], [@B10]). Δ-9-Tetrahydrocannabinol, being a partial agonist at cannabinoid receptor 1 (CB1) ([@B105]), a potential neurobiological mechanism for its adverse behavioral effects, resides on its ability to exert a CB1-mediated facilitatory effect on striatal and prefrontal dopaminergic neurotransmission ([@B111]), possibly through a disruption of glutamate signaling ([@B39]). This is in line with evidence for dopamine--glutamate aberrant interactions in psychosis and related cognitive dysfunction ([@B70]).

While Δ9-THC has shown moderate affinity for the CB1 receptor ([@B105]), synthetic cannabinoids have higher affinity, also showing full agonist action ([@B29]). Consistent with this, risk of severe acute ([@B103]; [@B26]) and long-lasting psychotic reactions for such compounds is much higher compared to Δ9-THC ([@B55]; [@B100]). This is relevant, as synthetic cannabinoid recreational use has increased considerably over the last decade ([@B80]).

In line with evidence that low-potency cannabis varieties with a more balanced Δ9-THC:CBD ratio are less harmful in terms of psychosis risk ([@B46]) and relapse ([@B113]), naturalistic studies have implied less prominent acute and residual cognitive impairments in high-CBD cannabis users ([@B98], [@B97]). Also, evidence is rapidly accumulating that CBD may prevent, reverse, or attenuate the Δ9-THC--induced aberrant behavior if administered before, after, or concomitantly ([@B30]). This seems to reflect opposite neurophysiological effects of Δ9-THC and CBD on prefrontal, striatal, and amygdalar substrates of psychiatric symptoms, such as psychosis and anxiety, as well as cognitive processes, such as verbal memory, response inhibition, fear processing, and auditory and visual stimuli processing ([@B14], [@B10], [@B7]). The question arising is whether such opposite biobehavioral effects of Δ9-THC and CBD would reflect opposite pharmacological activities on CB receptors. However, the ability of CBD to antagonize CB receptors *in vitro* ([@B121]) was not confirmed by subsequent evidence regarding the molecular pharmacology of CBD *in vivo* ([@B17]; [@B91]). It may be possible that CBD affects CB receptor activity *in vivo* in an indirect manner, through other molecular targets such as the regulation of intracellular calcium levels ([@B17]).

Cannabidiol concentrations needed to offset any harmful effects of Δ9-THC in healthy individuals are still unclear ([@B30]), and limited evidence suggests that CBD can exert different effects at different doses ([@B119]). In particular, CBD seems to reduce the intoxicating effect of Δ9-THC when coadministered at the dose of 400 mg, a dose falling within tested therapeutic ranges ([@B43]), while potentiating Δ9-THC--induced intoxication at the lower dose of 4 mg, a dose consistent with that allowed for non-medical use in some countries ([@B58]). Further, the effects of cannabinoids other than Δ9-THC and CBD, which may be present at different concentrations in illicit cannabis products, are mostly unknown. This is also relevant, as for instance limited evidence indicates that pretreatment with Δ-9-tetrahydrocannabivarin, a CB1 receptor neutral antagonist, prevents some of the cognitive alterations observed following acute exposure to Δ9-THC, such as impairments in delayed verbal memory recall, while exacerbating others, such as memory intrusions ([@B54]).

Understanding the Role of the Endocannabinoid System in Psychosis {#S2.SS3}
-----------------------------------------------------------------

Milestone discoveries in the understanding of the endocannabinoid system have been the identification of CB1 ([@B89]) and CB2 ([@B99]) receptors, as well as N-arachidonoyl-ethanolamine (AEA; anandamide) ([@B45]) and 2-arachidonoylglycerol (2-AG) ([@B93]), endogenous ligands at CB receptors ([@B48]). Derivatives of the arachidonic acid, AEA is a partial agonist at CB1 and CB2 receptors, whereas 2-AG is a full agonist ([@B48]), with both showing generally lower affinity for CB receptors than Δ9-THC ([@B92]). Both endocannabinoids are produced on demand, and their metabolites, obtained through enzymatic hydrolysis, show biological properties ([@B76]).

Cannabinoid receptor 1 receptor signaling in the brain is essential to modulate neurotransmitter release ([@B35]) and maintain neuronal activity in a balanced regimen ([@B131]). The evidence that Δ9-THC, CBD, and potentially other cannabis plant--derived cannabinoids may modulate CB1 receptor in the brain makes them competitors of the endocannabinoids at the same receptor, with important implications for the homeostasis of the endocannabinoid system ([@B105]). An altered endocannabinoid signaling has been independently implied in psychosis ([@B86]) from investigations of central nervous system biomarkers, suggesting ubiquitously higher CB1 receptor binding in the brain, lower levels of CB1 messenger RNA and protein in the prefrontal cortex, higher prefrontal metabolism of 2-AG, and elevated AEA levels in the cerebrospinal fluid ([@B124]; [@B96]), as well as evidence for higher AEA peripheral blood concentrations and higher CB1 receptor expression on peripheral immune cells ([@B96]). Very recent evidence indicates elevated endocannabinoid levels even in the peripheral blood of people at clinical high risk (CHR) of psychosis ([@B3]), that is, people presenting with prodromal or subsyndromal psychotic symptoms suggestive of a prepsychotic phase or attenuated psychosis syndrome ([@B60]), thus suggesting a perturbation of the endocannabinoid system in the early phases of the disorder. It is worth mentioning that studies measuring endocannabinoid levels in both the brain parenchyma and peripheral blood did not find any correlation between the alterations observed in the two body compartments ([@B96]). Further studies are needed to investigate whether they are independently associated with psychosis.

Cannabis-Based Potential Treatments for Psychosis and Cognitive Dysfunction {#S2.SS4}
---------------------------------------------------------------------------

Evidence that Δ9-THC and other direct-acting cannabinoid agonists can induce psychotic symptoms in both healthy individuals ([@B40]) and psychosis patients ([@B68]), and hyperactivity of the endocannabinoid system may independently promote the developmental cascade toward psychosis ([@B86]), fueled the study of CB1 receptor antagonist potential in schizophrenia. Unfortunately, evidence on the efficacy of such novel compounds was disappointing ([@B95]). Studies also revealed important side effects of CB1 receptor antagonists/inverse agonists, including provoking mood alterations and suicidal ideation ([@B74]). A promising strategy to improve the pharmacological and safety profile of CB receptor blockers is to shift from orthosteric to allosteric ligands. While orthosteric therapeutic compounds would compete with endocannabinoids at the CB1 receptor until metabolized, allosteric compounds would selectively target distinct CB1 receptor allosteric binding site(s), modulating the effect of endocannabinoids or other orthosteric ligands, such as Δ9-THC, only when and where active ([@B50]).

In this respect, CBD has also been suggested to be a non-competitive CB1 receptor antagonist, with low affinity for its primary ligand site but negative allosteric modulation properties allowing it to alter the potency of other primary ligands such as endocannabinoids and Δ9-THC in a dose-dependent manner ([@B79]). Despite lacking intrinsic efficacy, CBD would modulate the endocannabinoid tone, reducing CB1 receptor activity in the absence of the side effects previously found in CB1 inverse agonist trials ([@B28]), thus representing a promising CB receptor blocker. However, this potential mechanism of action does not exclude the possibility of an indirect modulation of the endocannabinoid system mediated by other molecular targets that, in conjunction with the allosteric binding, would contribute to the overall effects observed *in vivo*.

Not surprisingly, the antipsychotic potential of CBD has been the subject of evaluation since the 1990s, with 13 studies conducted so far ([@B43]). Such studies widely differ in terms of study design (open-label, placebo-controlled, comparative treatment, add-on treatment), sample size (*N* = 1--88), CBD dosage (300--1,500 mg/d), length of treatment (single dose, 6 months), psychiatric condition (schizophrenia, psychosis in Parkinson disease, CHR), and outcome measure (psychotic symptoms, psychosocial functioning, stress response, functional MRI, and cognitive processing). Early open-label case report, case series, and pilot studies indicate that a 4-week treatment with CBD reduces psychotic symptoms in schizophrenia ([@B135]) and Parkinson disease ([@B133]), but not in bipolar disorder ([@B132]), also reducing symptom severity in 1 of 3 patients with treatment-resistant schizophrenia ([@B134]). The first clinical trial providing solid evidence for CBD antipsychotic properties as monotherapy allocated schizophrenia patients to either CBD or the antipsychotic amisulpride up to 800 mg/d for 4 weeks, proving non-inferiority of CBD in reducing psychotic symptoms, with the advantage of a better tolerability profile ([@B82]). Such effect of CBD in reducing psychotic symptoms was not confirmed in a subsequent study where CBD was administered at the lower dose of 600 mg/d for 2 weeks only ([@B81]). More recently, a placebo-controlled study supported the efficacy of 1,000 mg/d CBD as add-on treatment in producing additional positive psychotic symptom reduction and overall clinical improvement in schizophrenia patients on an antipsychotic regimen for 6 weeks, with adverse events similar to placebo ([@B90]). Another study implementing the same methodology did not replicate such add-on effect of CBD at the lower dose of 600 mg/d in an older population of schizophrenia patients receiving long-term polypharmacy ([@B24]). Besides confirming a potential threshold dose--response curve, where higher CBD doses would be needed to reach antipsychotic effect ([@B41]), it also raises the questions whether CBD may be involved in drug-to-drug interactions whose effects are unclear and whether younger patients may benefit more from CBD treatment, because of earlier intervention in the pathophysiology of psychosis. Consistent with this, recent evidence supports the efficacy of a single dose of 600 mg CBD in normalizing aberrant brain function underlying psychotic symptoms in antipsychotic medication-naive CHR individuals (Bhattacharyya et al., 2018; [@B128]) and early psychosis patients ([@B102]). Also, additional evidence indicates that a 7-day treatment with 600 mg/d CBD may partially attenuate the altered responses to stress observed in CHR individuals ([@B2]). Altogether, these findings nourish hope that CBD may act as a disease-modifying drug.

Evidence for improving effects of CBD on cognition reveals a less linear dose--response effect ([@B43]). In a study of cognition in schizophrenia, 1-month treatment with CBD improved selective attention at the dose of 300 mg/d, while being less effective at the higher dose of 600 mg/d, possibly because of sedative effects in the higher-dose group ([@B64]). In another study, the same 600 mg/d regimen did not improve cognition among schizophrenia patients after 6 weeks of add-on treatment ([@B24]). Also, an add-on dose of 1,000 mg/d, the highest ever tested for cognitive effects in psychosis, failed to improve cognition significantly in a 6-week schizophrenia trial ([@B90]). Interestingly, a recent study indicates that a 400 mg CBD dose, while protecting against the intoxicating effects of Δ9-THC, exhibits intoxicating potential on its own in healthy individuals ([@B119]). Limited evidence also supports the ability of low CBD doses as 16 mg to improve emotional recognition acutely when administered to cannabis users ([@B69]). Altogether, compared to the effects of CBD on psychosis, evidence points in the direction of a narrower and potentially bell-shaped dose--response for the effects of CBD on cognition, with enhancing effects at low doses, which diminish to the extent of inducing intoxication/impairments at higher doses ([@B83]).

Discussion {#S3}
==========

The endocannabinoid system modulates a wide range of biological processes through life, ranging from neurodevelopment to neurodegeneration ([@B49]). It is thus plausible that pharmacological manipulation of the endocannabinoid signaling, depending on the direction of its effects ([@B105]), may have either deleterious consequences or therapeutic advantages. Consistent with this, depending on their Δ9-THC:CBD ratio, cannabis-derived drugs may have both pro-psychotic and antipsychotic as well as cognition-impairing and cognition-enhancing effects ([@B86]; [Figure 1](#F1){ref-type="fig"}). However, it is important to note that such model to explain the effects of cannabis on psychosis and cognition does not necessarily apply to other medical conditions. For instance, evidence points in the direction of a potential therapeutic role of Δ9-THC in multiple sclerosis spasticity, chronic pain management, weight loss associated with anorexia in AIDS, and chemotherapy-related nausea ([@B58]).

![Summary of the effects of Δ9-THC and CBD on psychosis and cognition. A deliberately simplistic interpretation of findings presented here is that cannabis-derived cannabinoids Δ9-THC and CBD, through their almost opposite partial agonist/agonist and antagonist/inverse agonist activity, might respectively, induce or blunt endocannabinoid system hyperactivity, resulting in pro-psychotic or antipsychotic effects as well as cognition-impairing or cognition-enhancing effects. However, despite producing opposite actions on the endocannabinoid system, Δ9-THC and CBD may exhibit even similar effects as activating or inhibiting the endocannabinoid system may produce both symptom amelioration and worsening depending on aging as well as different phases of psychosis or cognitive deterioration.](fpsyg-11-00833-g001){#F1}

Also, the endocannabinoid system function may change physiologically because of normal aging or be affected earlier in life in response to a neuropsychiatric condition and differently depending on its phases ([@B49]). This has implications for the homeostasis of other neurotransmitter systems, such as glutamate and dopamine, which also go through dynamic changes in health ([@B75]; [@B109]) and disease ([@B70]). It is therefore not unreasonable to speculate that Δ9-THC and CBD effects may vary depending on patients' aging and disease progression ([@B49]). Limited preclinical evidence suggests that low Δ9-THC doses may reverse the age-related decline in cognitive performance, while still impairing performance in youth ([@B18]). On the other hand, CBD does not seem to produce additional benefit as add-on treatment for psychosis patients in their middle age (≥45 years) ([@B24]), while ameliorating psychosis and tending to improve cognition ([@B90]), as well as normalizing underlying neurophysiological processes ([@B16]) in earlier phases of the disorder ([Figure 1](#F1){ref-type="fig"}).

Overall, evidence discussed here provides clarification for the multifaceted effects of cannabis on psychosis and cognition, by also navigating the complex role of the endocannabinoid system in both the harmful and therapeutic effects of cannabis-related products. These considerations provide a stepping-stone to the development of cannabinoid treatments for symptom amelioration and disease modification in psychosis. However, despite being promising, research in this field is still in its infancy, and we are far from clear-cut evidence that cannabinoids have a therapeutic role in psychosis or any other mental disorder ([@B19]). Future research will need to optimize the pharmacological manipulation of the endocannabinoid signaling, before any cannabis-related medical product for the treatment of psychosis and cognitive impairment might actually make it to the market.
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